Zucara Therapeutics is a biopharmaceutical company focused on developing innovative peptide therapies to address unmet medical needs in diabetes and bladder cancer. The company operates in the healthcare sector, specifically targeting intermediate and high-risk non-muscle invasive bladder cancer and Type 1 Diabetes (T1D). Zucara's lead product, ZT-01, is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with insulin-dependent diabetes. By restoring glucagon secretion, ZT-01 aims to prevent hypoglycemia, significantly improving the quality of life for patients with T1D. Additionally, Zucara is exploring novel peptide antagonists to enhance the effectiveness of chemotherapeutic treatments for bladder cancer, addressing the challenge of poor absorption in the urothelial tissue layer of the bladder. The company serves patients with diabetes and bladder cancer, operating in the pharmaceutical and biotechnology markets. Zucara's business model involves the development and commercialization of its proprietary therapies, generating revenue through product sales, partnerships, and licensing agreements. The company leverages its team's extensive experience in pharmaceuticals, vaccines, and diagnostics to advance its clinical programs and bring innovative treatments to market.

Keywords: peptide therapies, diabetes, bladder cancer, hypoglycemia, somatostatin, glucagon, ZT-01, biopharmaceutical, clinical trials, healthcare.